Catalina Capital Group LLC Buys Shares of 12,661 OmniAb, Inc. (NASDAQ:OABI)

Catalina Capital Group LLC bought a new stake in OmniAb, Inc. (NASDAQ:OABI) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 12,661 shares of the company’s stock, valued at approximately $69,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in OABI. ADAR1 Capital Management LLC purchased a new stake in shares of OmniAb during the fourth quarter worth $2,950,000. Federated Hermes Inc. purchased a new position in OmniAb in the fourth quarter valued at $38,000. Isthmus Partners LLC increased its holdings in OmniAb by 18.3% in the fourth quarter. Isthmus Partners LLC now owns 310,774 shares of the company’s stock valued at $1,917,000 after buying an additional 48,138 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in OmniAb by 56.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,772 shares of the company’s stock valued at $116,000 after buying an additional 6,755 shares during the last quarter. Finally, Jump Financial LLC increased its holdings in OmniAb by 157.1% in the fourth quarter. Jump Financial LLC now owns 49,732 shares of the company’s stock valued at $307,000 after buying an additional 30,386 shares during the last quarter. Hedge funds and other institutional investors own 72.08% of the company’s stock.

OmniAb Stock Performance

NASDAQ OABI traded up $0.09 during trading hours on Wednesday, hitting $4.13. The company had a trading volume of 557,575 shares, compared to its average volume of 548,156. OmniAb, Inc. has a 1-year low of $3.56 and a 1-year high of $6.72. The company has a market cap of $485.73 million, a PE ratio of -6.45 and a beta of -0.12. The business has a 50 day moving average of $4.26 and a 200-day moving average of $5.12.

OmniAb (NASDAQ:OABI) last announced its earnings results on Thursday, May 9th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02). OmniAb had a negative return on equity of 19.93% and a negative net margin of 301.62%. The business had revenue of $3.80 million for the quarter, compared to analyst estimates of $6.00 million. During the same quarter last year, the company posted ($0.06) EPS. Sell-side analysts expect that OmniAb, Inc. will post -0.66 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of OmniAb in a report on Thursday, March 21st. Benchmark reissued a “buy” rating and issued a $8.00 target price on shares of OmniAb in a report on Tuesday, May 14th. Truist Financial reissued a “buy” rating and issued a $10.00 target price on shares of OmniAb in a report on Tuesday, March 26th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $7.00 target price on shares of OmniAb in a report on Thursday, March 21st.

Insider Transactions at OmniAb

In other OmniAb news, CEO Matthew W. Foehr bought 240,000 shares of the firm’s stock in a transaction dated Friday, May 24th. The stock was acquired at an average price of $4.42 per share, for a total transaction of $1,060,800.00. Following the completion of the purchase, the chief executive officer now owns 3,536,665 shares of the company’s stock, valued at $15,632,059.30. The acquisition was disclosed in a filing with the SEC, which is available through this link. Insiders own 8.60% of the company’s stock.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.